Adaptive Biotechnologies (ADPT) has drawn fresh attention after recent share price moves, with the stock last closing at $24.77. Investors are weighing this valuation against the company’s immune medicine platform and oncology testing focus.

See our latest analysis for Adaptive Biotechnologies.

The recent share price recovery in Adaptive Biotechnologies has been strong, with a 90 day share price return of 91.13% and a 1 year total shareholder return of 99.60%. This builds on a 3 year total shareholder return of 284.63%, although the 5 year total shareholder return is still down 23.27%. This highlights both the momentum and the longer term volatility investors have experienced.

If you are comparing Adaptive Biotechnologies with other immune focused and diagnostics plays, it may be worth broadening your watchlist through the 40 healthcare AI stocks.

Bulls see Adaptive Biotechnologies as a high growth immune medicine platform now priced near analyst targets. Bears point to ongoing losses and a long road to scale. Which side do the current numbers support next?

Most Popular Narrative: 1% Undervalued

The most followed narrative currently pegs Adaptive Biotechnologies' fair value at $25.07, just above the last close at $24.77, which implies a very tight margin between modeled value and market pricing.

Substantial expansion in the MRD clinical pharma pipeline, evidenced by a growing clinical trial backlog (now at $218 million, up 21% over prior year) and increased use of clonoSEQ as a primary endpoint, forecasts future milestone payments and a high-quality revenue stream as regulatory momentum globally accelerates MRD adoption in drug development.

Read the complete narrative.

Want to see what underpins that near match between price and fair value? The narrative leans heavily on MRD growth, margin shifts, and a punchy earnings multiple.

Result: Fair Value of $25.07 (ABOUT RIGHT)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the story for Adaptive Biotechnologies can change quickly if MRD momentum slows or key partnerships such as Genentech or NeoGenomics disappoint expectations.

Find out about the key risks to this Adaptive Biotechnologies narrative.

Another View on Adaptive Biotechnologies' Valuation

The analyst narrative treats Adaptive Biotechnologies as roughly fairly priced around $25 based on long term growth and profitability forecasts. A simple reality check uses today’s P/S of 12.8x versus a fair ratio of 5.1x and an industry average of 4.1x. That gap suggests investors are already paying a steep premium for the story. Are you comfortable underwriting that much optimism?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment around Adaptive Biotechnologies split between optimism and caution, it makes sense to review the numbers yourself and decide quickly where you stand. To see what investors view as the main upside drivers, take a closer look at the 2 key rewards.

Looking for more investment ideas beyond Adaptive Biotechnologies?

If you want a broader context around Adaptive Biotechnologies, use the Simply Wall Street screener to spot other stocks that could sharpen your next move and keep you ahead.

• Target cash rich quality by checking companies that appear in the solid balance sheet and fundamentals stocks screener (50 results).
• Hunt for mispriced opportunities by scanning the screener containing 19 high quality undiscovered gems.
• Strengthen your defensive side by reviewing the 80 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.